Google
Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Septic Arthritis in Sickle Cell Anemia
source: Family Practice Notebook
year: 2018
summary/abstract:Septic Arthritis in Sickle Cell Anemia:
II. Causes
Staphylococcus aureus (most common cause)
Streptococcus Pneumoniae
Salmonella
III. Labs
Synovial Fluid (obtain in all suspected cases)
1. Normal Synovial Fluid cell count in >50% of Septic Arthritis cases
2. Gram Stain Test Sensitivity is only 50% (high False Negative Rate)
3. Synovial Fluid is the gold standard for diagnosis
IV. Management
A. Obtain Synovial Fluid culture and start empiric antibiotics
B. Total antibiotic course: 6 weeks
C. Initial empiric management
1. Cephaloporin sensitive
a. Ceftriaxone 50-75 mg/kg up to 2 g/dose OR
b. Ceftriaxone 75-100 mg/kg in high S. Pneumoniae resistance regions
2. Cephalosporin resistance
a. Clindamycin 10-15 mg/kg/dose (preferred) OR
b. Vancomycin 15 mg/kg/dose (if systemic Sepsis or Clindamycin reactions)
+myBinderRelated Content
-
Sickle cell trait and cognitive function in African Americans: The reasons for geographic and racial differences in ...Sickle cell anaemia (SCA) has been assoc...
-
FertilityIf you might want to have children in th...
-
SCD Patients Benefit From Early Rivipansel Treatment for VOCs, New Analyses ShowStarting treatment with rivipansel (GMI-...
-
Mental Health Resources for Black, Indigenous and People of Color (BIPOC)In addition to COVID-19, recent events h...
-
Patients With Sickle Cell Disease may Have Lower Risk for C. DifficileFindings from a retrospective cohort stu...
-
New Research Suggests SANGUINATE™ Reduces the Number of Sickled Red Blood Cells in Patients with Vaso-Occlusive Cr...SANGUINATE™, the only investigational ...
-
Multidisciplinary Care Team Greatly Reduces Risk in Pregnant SCD Patients in Low-income CountriesAccording to a study published in the Am...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.